BMEA
Price
$0.74
Change
-$0.10 (-11.90%)
Updated
Oct 20 closing price
Capitalization
53.32M
14 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$2.58
Change
+$0.16 (+6.61%)
Updated
Oct 20 closing price
Capitalization
396.24M
19 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BMEA vs EDIT

BMEA vs EDIT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BMEA vs. EDIT commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMEA is a Buy and EDIT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BMEA with price predictions
Oct 19, 2026

BMEA in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026

BMEA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 31 cases where BMEA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMEA advanced for three days, in 231 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMEA as a result. In 66 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

BMEA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BMEA crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMEA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BMEA entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BMEA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.393) is normal, around the industry mean (2.978). P/E Ratio (-4.087) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMEA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for EDIT with price predictions
Oct 20, 2026

EDIT's Stochastic Oscillator is sitting in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 79 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for EDIT entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.764) is normal, around the industry mean (3.009). P/E Ratio (-3.909) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDIT: Fundamental Ratings
EDIT
OUTLOOK RATING
1..100
84
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
77
P/E GROWTH RATING
1..100
27
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BMEAEDIT
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (BMEA: $0.74 vs. EDIT: $2.58)
Brand notoriety: BMEA and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMEA: 164% vs. EDIT: 63%
Market capitalization -- BMEA: $53.32M vs. EDIT: $396.24M
BMEA [@Biotechnology] is valued at $53.32M. EDIT’s [@Biotechnology] market capitalization is $396.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.44B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMEA’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).

  • BMEA’s FA Score: 1 green, 4 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, BMEA is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMEA’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • BMEA’s TA Score: 4 bullish, 5 bearish.
  • EDIT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BMEA is a better buy in the short-term than EDIT.

Price Growth

BMEA (@Biotechnology) experienced а -41.62% price change this week, while EDIT (@Biotechnology) price change was +5.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.

Reported Earning Dates

BMEA is expected to report earnings on Nov 03, 2026.

EDIT is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BMEA
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
USTC.X0.0050370.000180
+3.70%
TerraClassicUSD cryptocurrency
QTUM.X0.8777450.016629
+1.93%
Qtum cryptocurrency
HBAR.X0.0842620.001327
+1.60%
Hedera cryptocurrency
BTCST.X0.0101710.000141
+1.41%
Bitcoin Standard Hashrate Token cryptocurrency
SANTOS.X0.477821-0.000207
-0.04%
Santos FC Fan Token cryptocurrency

BMEA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMEA has been loosely correlated with PROK. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BMEA jumps, then PROK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMEA
1D Price
Change %
BMEA100%
-11.96%
PROK - BMEA
43%
Loosely correlated
+3.23%
VYGR - BMEA
39%
Loosely correlated
+6.83%
CAI - BMEA
38%
Loosely correlated
+1.30%
EDIT - BMEA
37%
Loosely correlated
+6.61%
MGX - BMEA
36%
Loosely correlated
+2.40%
More